Legend Biotech(LEGN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, revenue reached $306 million, reflecting a 64% year-over-year growth, with a gross margin of 61% [24][26] - The operating margin improved from -142% in Q2 2023 to -6% in Q4 2025, indicating significant operational leverage [24][26] - Adjusted net income was reported at $2.5 million, a transformation from a $59 million adjusted net loss a year ago [26] Business Line Data and Key Metrics Changes - CARVYKTI net trade sales were approximately $555 million in Q4 2025, a 66% increase year-over-year and a 6% increase from Q3 2025 [7][16] - U.S. net trade sales of CARVYKTI were $420 million, growing 38% year-over-year [16] - Outside the U.S., sales reached $135 million, representing over a threefold increase compared to the same period a year ago [16] Market Data and Key Metrics Changes - CARVYKTI is now offered in 14 global markets, with 294 treatment sites worldwide [16][18] - The majority of CARVYKTI utilization is in earlier line settings, with approximately 65% of patients treated in the second to fourth line settings [16][22] - The market for BCMA-directed therapies remains under-penetrated, with less than 5% of patients in the second through fourth line treated with a BCMA targeting agent in 2025 [17] Company Strategy and Development Direction - The company aims to achieve company-wide profitability in 2026, following CARVYKTI's profitability in 2025 [7][15] - There is a strategic focus on expanding CARVYKTI's use in earlier treatment lines, supported by clinical evidence showing better outcomes [17][23] - The partnership with Johnson & Johnson is aimed at scaling CARVYKTI to an anticipated peak annual sales potential of over $5 billion [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential growth throughout 2026, targeting approximately 50% top-line growth from the previous year [31] - The company is optimistic about the long-term growth potential of CARVYKTI, given the significant unmet needs in the multiple myeloma market [17][24] - Management highlighted the importance of effective bridging therapy in improving patient outcomes and safety [19][22] Other Important Information - The company ended the year with $949 million in cash equivalents, providing flexibility for future investments [27] - The Tech Lane facility in Belgium began commercial production in September 2025, supporting growth in ex-U.S. markets [16][17] - The company plans to file one to two U.S. INDs by the end of the year, focusing on advancing its R&D pipeline [14] Q&A Session Summary Question: Expectations for CARVYKTI growth in 2026 - Management expects sequential growth throughout 2026, confident in achieving approximately 50% top-line growth from last year [31] Question: Focused synergistic business development - The company is interested in complementary technologies and potential partnerships to accelerate the development of in vivo CAR T assets [32] Question: Positioning of bispecifics relative to CARVYKTI - Management believes there is a significant unmet need in second and third line settings, with a unique value proposition for CARVYKTI [35] Question: Community setting expansion hurdles - Continued education and training for community physicians are essential for expanding CARVYKTI's adoption in community hospitals [39] Question: Current CAR-T penetration targets - The company sees significant growth potential in both late-line and early-line multiple myeloma treatments, with a focus on improving patient outcomes [44][46] Question: Impact of recent M&A in the space - The acquisition of a competitor validates the market's value, with the company prepared for increased competition [58][59] Question: MRD results and potential filing acceleration - The company is exploring the correlation between MRD activity and clinical outcomes, which could accelerate FDA filing times for future trials [70]